3098670-37-9
Chemical Structure
MS9117
- CAS No.: 3098670-37-9
- Formula:C46H48F2N10O10
- Molecular Weight:938.93
InChIKey: ANKXTUZTSWPMGD-UHFFFAOYSA-N
SMILES: N#CC1=CC=C(C(N=C(N2CCC(CC2)N)N3CC(NCCOCCOCCNC(CNC4=CC=CC(C(N5C6C(NC(CC6)=O)=O)=O)=C4C5=O)=O)=O)=C(C7=CC(F)=C(OC)C=C7)C3=O)C=C1F
Biological Activity: MS9117 is a PROTAC molecule that targets and degrades LSD1/BHC110 by recruiting CRBN. MS9117 effectively increases the level of histone H3 lysine 4 monomethylation. MS9117 significantly inhibits the proliferation and colony formation of cancer cells, promotes their myeloid differentiation, and enhances the sensitivity of non-acute promyelocytic leukemia-type AML cells to all-trans retinoic acid (ATRA)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MS9117 | MS9117 is a PROTAC molecule that targets and degrades LSD1/BHC110 by recruiting CRBN. MS9117 effectively increases the level of histone H3 lysine 4 monomethylation. MS9117 significantly inhibits the proliferation and colony formation of cancer cells, promotes their myeloid differentiation, and enhances the sensitivity of non-acute promyelocytic leukemia-type AML cells to all-trans retinoic acid (ATRA). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hosseini A, et al. Discovery of an LSD1 PROTAC degrader. Proceedings of the National Academy of Sciences of the United States of America. 2025 May 20;122(20):e2425812122. [Content Brief]
- [2]. Khan SA, et al. Therapeutic advances in acute myeloid leukemia: from LSD1 blockade to PROTAC-based strategies. Annals of medicine and surgery (2012). 2026 Feb;88(2):2166-2167. [Content Brief]
